Samrat Pharmachem Ltd Financials
Company Logo

Samrat Pharmachem Ltd Financial Statement

Samrat Pharmachem Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue70.66
Operating Expense66.81
Net Profit2.66
Net Profit Margin3.76
Earning Per Share8.60
EBIDTA4.43
Effective Tax Rate37.14
Invest in Samrat Pharmachem Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Samrat Pharmachem Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual281.58
Operating Expenses Annual279.11
Operating Profit Annual3.85
Interest Annual0.69
Depreciation0.65
Net Profit Annual2.16
Tax Annual0.36

Samrat Pharmachem Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning11.86
Cash Flow from Operations9.41
Cash Flow from Investing-0.41
Cash Flow from Financing-11.20
Cash Flow at the End9.67

Samrat Pharmachem Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)1.37
PBIT Margin (%)1.14
PBT Margin (%)-0.51
Net PROFIT Margin (%)0.77
Return On Networth / Equity (%)3.37
Return On Networth /Employed (%)4.14
Return On Assets (%)2.78
Total Debt / Equity (X)0.21
Asset Turnover Ratio (%)3.63

Samrat Pharmachem Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual10.72
Total Current Assets Annual102.57
Non Current Assets Annual19.17
Total Shareholders Funds Annual65.00
Total Assets Annual121.74

Samrat Pharmachem Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 23, 2024, Samrat Pharmachem Ltd has a market capitalization of 103.04 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Samrat Pharmachem Ltd is debt-free with a debt-to-equity ratio of 0.13.
In FY 2023 , Samrat Pharmachem Ltd recorded a total revenue of approximately 281.58 Cr marking a significant milestone in the company's financial performance.
Samrat Pharmachem Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.2% and 0.1% annually, respectively..
Samrat Pharmachem Ltd's current PE ratio is 47.70.
Samrat Pharmachem Ltd's ROCE averaged 26.0% from the FY ending March 2022 to 2024, with a median of 29.0%. It peaked at 44.7% in March 2022, reflecting strong capital efficiency over the period..
Samrat Pharmachem Ltd's latest EBIT is Rs. 3.21 Cr, surpassing the average EBIT of Rs. 17.08 Cr over the 5 years..